Table 4.
Number of hypermethylated markers in recurrent lesions
|
Sensitivity (%) |
Specificity (%) |
Accuracy (%) |
|
|---|---|---|---|
| (95%CI) | (95%CI) | (95%CI) | |
|
a) FHIT, MLH1, ATM |
|
|
|
|
≥1 |
61.29 (43.82-76.27) |
93.61 (82.84-97.81) |
80.76 (72.02-89.52) |
|
≥2 |
22.58 (11.40-39.81) |
100 (92.44-100) |
69.23 (58.99-79.47) |
|
≥3 |
6.45 (1.79-20.72) |
100 (92.44-100) |
62.82 (52.09-73.55) |
|
b) FHIT, MLH1, ATM, TP73, BRCA1 |
|
|
|
|
≥1 |
70.96 (53.41-83.90) |
85.11 (72.31-92.59) |
79.49 (70.53-88.45) |
|
≥2 |
38.71 (23.73-56.18) |
95.74 (85.75-98.83) |
73.08 (63.24-82.92) |
|
≥3 |
16.13 (7.09-32.63) |
100 (92.44-100) |
66.66 (56.21-77.13) |
|
≥4 |
6.45 (1.79-20.72) |
100 (92.44-100) |
62.82 (52.09-73.55) |
|
≥5 |
3.22 (0.57-16.19) |
100 (92.44-100) |
61.53 (50.74-72.34) |
|
c) FHIT, MLH1 |
|
|
|
|
≥1 |
58.06 (40.77-73.58) |
95.74 (85.75-98.83) |
80.77 (72.02-89.52) |
| ≥2 | 9.68 (3.35-24.90) | 100 (92.44-100) | 64.10 (53.45-74.75) |
Sensitivity, R patients who were correctly identified by the hypermethylated profile; Specificity, NR patients who were correctly identified by the hypermethylated profile; Accuracy, R patients, correctly identified by the hypermethylated profile, and NR patients, correctly identified by the hypermethylated profile, divided by the total series; 95% CI, 95% confidence intervals.